Comparative in vitro dissolution study of carbamazepine immediate-release products using the USP paddles method and the flow-through cell system

Saudi Pharmaceutical Journal

Volumn 22, Issue 2, 2014, Pages 141-147

  Medina, José Raúl ^a   Salazar, Dulce Karina ^a   Hurtado, Marcela ^a   Cortés, Alma Rosa ^a   Domínguez Ramírez, Adriana Miriam ^a  

^a DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

Author keywords

Antiepileptics; Carbamazepine; Dissolution rate; Flow through cell system; Generic products

Indexed keywords

CARBAMAZEPINE;

ANALYTIC METHOD; ARTICLE; COMPARATIVE STUDY; DRUG BIOAVAILABILITY; DRUG RELEASE; DRUG SOLUBILITY; FLOW THROUGH CELL SYSTEM; IN VITRO STUDY; TABLET; USP PADDLES METHOD;

EID: 84895487366     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsps.2013.02.001     Document Type: Article

References (41)

1. Amidon G.L., Lennernäs H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research 1995, 12:413-420.
2. Barakat N.S., Elbagory I.M., Almurshedi A.S. Controlled-release carbamazepine matrix granules and tablets comprising lipophilic and hydrophilic components. Drug Delivery 2009, 16:57-65.
3. Bønløkke L., Hovgaard L., Kristensen H.G., Knutson L., Lindahl A., Lennernäs H.A. Comparison between direct determination of in vivo dissolution and the deconvolution technique in humans. European Journal of Pharmaceutical Sciences 1999, 8:19-27.
4. Cardot J.M., Beyssac E., Alrici M. In vitro-in vivo correlation: importance of dissolution in IVIVC. Dissolution Technologies 2007, 14:15-19.
5. Castro N., Jung H. Determination of absorption profiles of carbamazepine products by the deconvolution method and its correlation with in vitro data. Revista Mexicana de Ciencias Farmacéuticas 2000, 31:42-46.
6. Chevalier E., Viana M., Artaud A., Chomette L., Haddouchi S., Devidts G., Chulia D. Comparison of three dissolution apparatuses for testing calcium phosphate pellets used as ibuprofen delivery systems. AAPS PharmSciTech 2009, 10:597-605.
7. Davidson A.G. A multinational survey of the quality of carbamazepine tablets. Drug Development and Industrial Pharmacy 1995, 21:2167-2186.
8. Emara L.H., El-Menshawi B.S., Estefan M.Y. In vitro-in vivo correlation and comparative bioavailability of vincamine in prolonged-release preparations. Drug Development and Industrial Pharmacy 2000, 26:243-251.
9. Food and Drug Administration, 1999. Guidance for industry waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms containing certain active moieties/active ingredients based on a biopharmaceutics classification system. Center for Drug Evaluation and Research (CDER), U.S. Department of Health and Human Services.
10. Fotaki N., Symillides M., Reppas C. In vitro versus canine data for predicting input profiles of isosorbide-5-mononitrate from oral extended release products on a confidence interval basis. European Journal of Pharmaceutical Sciences 2005, 24:115-122.
11. Gidal B.E., Tomson T. Debate: substitution of generic drugs in epilepsy: is there cause for concern?. Epilepsia 2008, 49:56-62.
12. Girad M.E., Millán R., Jung H., Torres S., Montoya M.A. Dissolution study of carbamazepine tablets. Revista Mexicana de Ciencias Farmacéuticas 1996, 27:13-17.
13. Greco K., Bergman T.L., Bogner R. Design and characterization of a laminar flow-through dissolution apparatus: comparison of hydrodynamic conditions to those of common dissolution techniques. Pharmaceutical Development and Technology 2011, 16:75-87.
14. Hamlin W.E., Nelson E., Ballard B.E., Wagner J.G. Loss of sensitivity in distinguishing real differences in dissolution rates due to increasing intensity of agitation. Journal of Pharmaceutical Sciences 1962, 51:432-435.
15. Hurtado M., Vargas Y., Domínguez-Ramírez A.M., Cortés A.R. Comparison of dissolution profiles for albendazole tablets using USP Apparatus 2 and 4. Drug Development and Industrial Pharmacy 2003, 29:777-784.
16. Jinno J., Kamada N., Miyake M., Yamada K., Mukai T., Odomi M., Toguchi H., Liversidge G.G., Higaki K., Kimura T. In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol. Journal of Controlled Release 2008, 130:29-37.
17. Jung H., Milán R.C., Girard M.E., León F., Montoya M.A. Bioequivalence study of carbamazepine tablets: in vitro/in vivo correlation. International Journal of Pharmaceutics 1997, 152:37-44.
18. Khan K.A. The concept of dissolution efficiency. Journal of Pharmacy and Pharmacology 1975, 27:48-49.
19. Koester L.S., Ortega G.G., Mayorga P., Bassani V.L. Mathematical evaluation of in vitro profiles of hydroxypropylmethylcellulose matrix tablets containing carbamazepine associated to β-cyclodextrin. European Journal of Pharmaceutics and Biopharmaceutics 2004, 58:177-179.
20. Lake O.A., Olling M., Barends D.M. In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers. European Journal of Pharmaceutics and Biopharmaceutics 1999, 48:13-19.
21. Langenbucher F., Benz D., Kurth W., Moller H., Otz M. Standardized flow-cell method as an alternative to existing pharmacopoeial dissolution testing. Pharmaceutical Industry 1989, 51:1276-1281.
22. Langenbucher F. Linearization of dissolution rate curves by the Weibull distribution. Journal of Pharmacy and Pharmacology 1972, 24:979-981.
23. Lindenberg M., Kopp S., Dressman J.B. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. European Journal of Pharmaceutics and Biopharmaceutics 2004, 58:265-278.
24. Medina J.R., Hurtado M., Cortés A.R., Aoki K., Domínguez A.M. Dissolution of paracetamol suppositories using the flow-through cell system and their absorption in an animal model. Revista Mexicana de Ciencias Farmacéuticas 2009, 40:11-18.
25. Meyer M.C., Straughn A.B., Jarvi E.J., Wood G.C., Pelsor F.R., Shah V.P. The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharmaceutical Research 1992, 9:1612-1616.
26. Mittapalli P.K., Suresh B., Hussaini S.S.Q., Rao Y.M., Apte S. Comparative in vitro study of six carbamazepine products. AAPS PharmSciTech 2008, 9:357-365.
27. Moore J.W., Flanner H.H. Mathematical comparison of dissolution profiles. Pharmaceutical Technology 1996, 20:64-74.
28. Norma Oficial Mexicana, 1999. NOM-177-SSA1-1998 Diario Oficial de la Federación, México DF, p. 44-67.
29. Okumu A., Dimaso M., Löbenberg R. Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug. Pharmaceutical Research 2008, 25:2778-2785.
30. Olling M., Mensinga T.T., Barends D.M., Groen C., Lake O.A., Meulenbelt J. Bioavailability of carbamazepine from four different products and the occurrence of side effects. Biopharmaceutics and Drug Disposition 1999, 20:19-28.
31. Podczeck F. Comparison of in vitro dissolution profiles by calculating mean dissolution time (MDT) or mean residence time (MRT). International Journal of Pharmaceutics 1993, 97:93-100.
32. Qureshi S.A., Caillé G., Brien R., Piccirilli G., Yu V., Mc Gilveray I.J. Application of flow-through dissolution method for the evaluation of oral formulations of nifedipine. Drug Development and Industrial Pharmacy 1994, 20:1869-1882.
33. Rentmeester T.W., Doelman J.C., Hulsman J.A. Carbamazepine: branded formulation versus generic formulation. Pharma Weekblad 1990, 125:1108-1110.
34. Shaw S.J., Krauss G.L. Generic antiepileptic drugs. Current Treatment Options in Neurology 2008, 10:260-268.
35. Shiko G., Gladden L.F., Sederman A.J., Connolly P.C., Butler J.M. MRI studies of the hydrodynamics in a USP 4 dissolution testing cell. Journal of Pharmaceutical Sciences 2011, 100:976-991.
36. United States Pharmacopeia (USP 30) 2007. United States Pharmacopeial Convention.
37. Uznović A., Vranić E., Hadžidedić Š. Impairment of the in vitro release of carbamazepine from tablets. Bosnian Journal of Basic Medical Sciences 2010, 10:234-238.
38. Volonté M.G., Viñas M.A., De Buschiazzo P.M., Piersante M.V., Escales M.C., Gorriti C.E. Comparative study of carbamazepine 200 mg tablets for pharmaceutical equivalence determination. Acta Farmacéutica Bonaerense 2004, 23:391-397.
39. Yuksel N., Kanik A.E., Baykara T. Comparison of in vitro dissolution profiles by ANOVA-based, model-dependent and independent-methods. International Journal of Pharmaceutics 2000, 209:57-67.
40. Zhang G.H., Vadinno W.A., Yang T.T., Cho W.P., Chaudry I.A. Evaluation of the flow-through cell dissolution apparatus: effects of flow rate, glass beads and tablet position on drug release from different type of tablets. Drug Development and Industrial Pharmacy 1994, 20:2063-2078.
41. Zhang Y., Huo M., Zhou J., Zou A., Li W., Yao C., Xie S. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS Journal 2010, 12:263-271.